This study is about treating advanced lung cancer, specifically non-small cell lung cancer (NSCLC), with a new drug called **sacituzumab tirumotecan**. This drug will be compared to traditional chemotherapy treatments. The study focuses on patients who have specific changes, called *mutations*, in their genes. Some of these mutations include changes in EGFR, ALK, and BRAF genes, which can affect how cancer grows.

**Key points to consider:**

• The study involves comparing two treatments: the new drug vs. standard chemotherapy.
• To participate, you need specific genetic mutations and must have tried certain treatments before.
• You can join if you have controlled infections like Hepatitis B or HIV.

To join, you must have advanced lung cancer that can't be removed or cured with radiation. You should have tried one or two treatments before, including a specific type of drug called EGFR TKI. You can't join if you have other serious health issues, like certain infections or heart diseases. If you've had brain cancer that's now stable, you may still participate. This study aims to see if the new drug helps people live longer or slows cancer growth more effectively than current treatments.